HIGH YIELD | HIGH PURITY | HIGH ACTIVITY
Introducing the CL-7 affinity tag system
Proteins play a central role in biotech and pharmaceutical research. As many as 80 percent of all drugs in development are either based on select proteins or act on proteins. More than a thousand drug candidates remain unexplored due to protein-related problems, with as many as a third of all membrane proteins having not been isolated at all.
That is why TriAltus Bioscience is working to transform protein-based research, making it easier and more affordable to obtain high-quality materials needed in the lab.
We believe researchers want to spend more time making discoveries in the search for new therapeutics, and less time working to produce their target proteins in the purity and quantity needed. Learn more about how our CL-7 affinity tag purification system can help.
Management Team
Bob Shufflebarger
Dmitry Vassylyev, PhD
Media & Scientific Publications
Chinese Scientists Use TriAltus Bioscience’s CL-7 Purification System to Purify CRISPR-associated Proteins
BIRMINGHAM, Ala. (August 29, 2018)—TriAltus Bioscience, LLC today announced that scientists at Hubei University in China successfully co-expressed and purified ribonucleoprotein complexes—including Cas9 and Cas12a CRISPR-associated proteins—from E. coli in a single step using the company’s licensed CL-7 purification technology. The Hubei scientists published the results of their work in late July. “This team’s success […]
TriAltus Bioscience: One of the Bioscience Companies to Watch
TriAltus Bioscience has been recognized by the Birmingham Business Alliance as one of its bioscience companies to watch in this growing industry sector. Read more.
The TriAltus Bioscience Origin Story
What prompted the commercialization of our CL-7 protein purification system? After the PNAS paper, this article appeared in the UAB News. Learn why we thought CL-7 was so interesting. Read more.